July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Routine preop tests catch hidden risks in outpatient cosmetic surgery, Canadian study finds
- Study: Hospital same‑day knee replacements match ASC outcomes, even in higher‑risk patients
- FDA clears AI platform for real-time surgical measurements
- Study: MRI contrast agent causes harmful metal buildup in some patients
- Dissolvable pacemaker delivers temporary cardiac support without wires, surgery
- CSA taps Milagro’s AI coding to accelerate revenue cycle across ASC network
- Study: Cannabis use complicates sedation, cancer care
- Medication vial coring incidents prompt patient safety concerns
- First single-port robotic renal vein transposition surgery treats nutcracker syndrome
- Study: Mortality prediction models fail to recognize severe patient injuries
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement